WilmerHale Reps Apellis Pharmaceuticals in $60 Million Series E Financing

WilmerHale Reps Apellis Pharmaceuticals in $60 Million Series E Financing

Firm News

On August 10, 2017, Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, announced the closing of a $60 million Series E preferred stock financing.

WilmerHale represented Apellis in this transaction, with a team led by Stuart Falber and included Mhairi Immermann and Alicia Lee.

Read Apellis' press release

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.